Natco Pharma shares jump 5% after US FDA's tentative approval for Olaparib tablets
Indian pharma giant gains FDA nod for generic cancer drug, boosting market prospects.
1FDA approval drives surge
Natco Pharma shares rose 4.5% after receiving tentative FDA approval for its generic version of Olaparib tablets. The 100mg and 150mg dosages are bioequivalent to AstraZeneca's Lynparza. This regulatory milestone strengthens Natco's position in the lucrative US pharmaceutical market, though final approval awaits patent litigation resolution.
2Market potential unveiled
Olaparib tablets recorded $1.4 billion in annual US sales. While Natco will manufacture the drug, marketing partner Alembic Pharmaceuticals will handle US distribution. The product's commercial success hinges on overcoming ongoing patent challenges, which will significantly impact Natco's growth trajectory in oncology therapeutics.
3African expansion strategy
Prior to the FDA news, Natco increased its stake in South Africa's Adcock Ingram from 35.75% to 49% for ZAR 1.81 billion. This strategic investment in Africa's pharmaceutical leader demonstrates Natco's commitment to global expansion. The move could provide long-term growth as the company diversifies beyond traditional markets.
4Stock performance snapshot
Despite reaching Rs 987.55, Natco shares remain below their 52-week high of Rs 1,226.80. With a market cap of Rs 16,925 crore, the stock trades at reasonable valuations (P/E 11.93, P/B 1.83) compared to pharma peers. Technical indicators show neutral momentum, with the stock maintaining support above key long-term moving averages.
5Institutional investor trends
June 2026 quarter data revealed contrasting trends: FIIs reduced holdings from 17.37% to 16.99%, while domestic mutual funds increased stakes from 1.72% to 1.92%. This divergence reflects foreign investors' caution versus domestic confidence in Natco's strategic direction. Pending regulatory outcomes may reshape these investment patterns.
6Industry significance
Natco's FDA approval marks a critical achievement for generic drugmakers targeting the world's largest pharmaceutical market. The high demand for cancer treatments and successful African expansion position Natco for sustainable growth. As the company strengthens its transcontinental presence, it aims to become a more influential player in global healthcare innovation.
Original article: Economic Times — Natco Pharma hisseleri FDA onayı sonrası yükseldi